William Blair Comments on AZEK’s Q3 Earnings (NYSE:AZEK)
Stock analysts at William Blair raised their Q3 2025 earnings per share estimates for AZEK in a research note issued on ...
William Blair Names John Ivey, B.T. Remmert Co-Heads of Technology Investment Banking
William Blair, the premier global boutique with expertise in investment banking, investment management, and private wealth management, has named managing directors John Ivey and B.T. Remmert as the ...
William Blair Has Bearish Forecast for BMY FY2026 Earnings
Equities research analysts at William Blair decreased their FY2026 earnings per share estimates for shares of Bristol-Myers ...
Hosted on MSN4d
William Blair Downgrades WEX (WEX)
Fintel reports that on February 7, 2025, William Blair downgraded their outlook for WEX (NYSE:WEX) from Outperform to Market ...
Mersana Therapeutics initiated with an Outperform at William Blair
William Blair initiated coverage of Mersana Therapeutics (MRSN) with an Outperform rating.Maximize Your Portfolio with Data Driven ...
Business Insider4d
William Blair downgrades Sprinklr to Market Perform on transition period
William Blair downgraded Sprinklr (CXM) to Market Perform from Outperform without a price target after the company announced a 15% global workforce reduction. While expectations are low for the ...
Why Is Neurocrine Biosciences Stock Trading Lower On Friday?
Neurocrine Biosciences Inc. (NASDAQ:NBIX) reported fourth-quarter adjusted EPS of $1.69, higher than the $1.54 reported a ...
Yahoo Finance29d
William Blair Expands Biopharma Investment Banking Group With Senior Hire
CHICAGO, January 13, 2025--(BUSINESS WIRE)--William Blair, the premier global boutique with expertise in investment banking, investment management, and private wealth management, today announced ...
FiercePharma1d
With Teva competition heating up, Neurocrine's tame Ingrezza forecast spooks investors
Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...